LY341495

LY-341,495

Identifiers
IUPAC name 2-[(1S,2S)-2-carboxycyclopropyl]-3-(9H-xanthen-9-yl)-D-alanine
Synonyms	(2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl)propanoic acid
CAS Number	201943-63-7 Y
ChemSpider	7995676 N
Chemical and physical data
Formula	C20H19NO5
Molar mass	353.37 g/mol
3D model (Jmol)	Interactive image
SMILES C1[C@@H]([C@H]1[C@@](CC2C3=CC=CC=C3OC4=CC=CC=C24)(C(=O)O)N)C(=O)O
InChI InChI=1S/C20H19NO5/c21-20(19(24)25,15-9-13(15)18(22)23)10-14-11-5-1-3-7-16(11)26-17-8-4-2-6-12(14)17/h1-8,13-15H,9-10,21H2,(H,22,23)(H,24,25)/t13-,15-,20-/m0/s1 N Key:VLZBRVJVCCNPRJ-KPHUOKFYSA-N N
NY (what is this?)

LY-341,495 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as a potent and selective orthosteric antagonist for the group II metabotropic glutamate receptors (mGluR_2/3).

It is used in scientific research in several different areas, showing antidepressant effects in animal models, increasing the behavioural effects of hallucinogenic drugs in animal tests, and increasing the analgesic effects of μ-opioid agonists, as well as modulating dopamine receptor function.

The 1-fluorocyclopropane analog has a superior pharmacokinetic profile and similar mGluR_2/3 affinity, and making a prodrug from this with the heptyl ester increases bioavailability still further.